Nanocopoeia patents expiration
1. Phyrago patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11324745 | NANOCOPOEIA | Amorphous solid dispersions of dasatinib and uses thereof |
Jan, 2041
(16 years from now) | |
| US11202778 | NANOCOPOEIA | Amorphous solid dispersions of dasatinib and uses thereof |
Jan, 2041
(16 years from now) | |
| US11298356 | NANOCOPOEIA | Amorphous solid dispersions of dasatinib and uses thereof |
Jan, 2041
(16 years from now) | |
Drugs and Companies using DASATINIB ingredient
Market Authorisation Date: 05 December, 2023
Treatment: Use of dasatinib for treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase ph+ cml with resistance or intolerance to prior therapy including imatinib, when administered at ...
Dosage: TABLET;ORAL
More Information on Dosage
PHYRAGO family patents
